Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia - VUHEM-MRD-2013

Vrije Universiteit Medisch Centrum0 个研究点目标入组 31 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•*Patients with Acute Myeloid Leukemia according to WHO classification 2008
•*Age 18-75
•*Indication for allogeneic stem cell transplantation based on risk group profile
•*Related or unrelated 8/8 HLA matched donor available
•*Presence of Leukemia Associated Phenotype(s) (LAPs)
•*Written informed consent

•-Myelodysplastic syndrome with refractory anaemia with excess blasts (RAEB)
•Acute Promyelocytic Leukemia (AML M3)
•-Absence of LAP(s)
•-Previous allogeneic stem cell transplantation
•-Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease)
•*Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D)
•*Severe neurological or psychiatric disease
•*Significant hepatic dysfunction (serum bilirubin or transaminases * 3 times upper limit of normal) unless related to treatment
•*Significant renal dysfunction (creatinine clearance < 30 ml/min after rehydration)
•*Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.)
•*Patient known to be HIV-positive
•*Pregnant or breast-feeding female patients
•*Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule

发起方